The “addition” and “subtraction” of adjuvant chemotherapy for locally advanced colorectal cancer: where to go next?

0
0
0

The “addition” and “subtraction” of adjuvant chemotherapy for locally advanced colorectal cancer: where to go next?

For patients with locally advanced colorectal cancer (CRC)—a disease affecting millions worldwide—surgery alone isn’t always enough. Post-operative adjuvant chemotherapy (ACT) has saved lives by lowering recurrence risk and extending survival. But as treatments have evolved, oncologists face a critical question: How can we maximize benefits while minimizing harmful side effects?

This is the focus of a 2019 viewpoint by Xin-Hua Chen, Zhou-Sheng Lin (co-first authors), and Jiang Yu from Southern Medical University’s Nanfang Hospital and Second Clinical Medical School in Guangzhou, China. Their analysis of decades of clinical trials offers a roadmap for balancing “addition” (adding drugs like oxaliplatin) and “subtraction” (reducing treatment duration or intensity) to create more personalized, patient-centered care.

The Rise of Oxaliplatin: A Game-Changer—But at a Cost

For years, fluorouracil (5-FU) was the backbone of adjuvant therapy for stage III CRC. Then, three landmark trials changed the game:

  • MOSAIC (2004): Adding oxaliplatin to 5-FU/leucovorin (FL) improved 3-year disease-free survival (DFS, time without recurrence) from 72.9% to 78.2% in stage II/III CRC.
  • NSABP C-07 (2007): Oxaliplatin boosted 3-year DFS by 6.6% compared to FL alone.
  • NO16968 (2011): Capecitabine plus oxaliplatin (CAPOX) led to a 7-year DFS of 63%—7% higher than 5-FU/folinic acid.

These results made a 6-month oxaliplatin-based regimen the gold standard for healthy stage III CRC patients. But the win came with a catch: oxaliplatin causes severe, sometimes irreversible neurotoxicity (nerve damage), along with nausea, low blood counts, and other side effects. For many, the trade-off between survival and quality of life was tough—and excessive treatment could even weaken the immune system, doing more harm than good.

When Less Is More: The Case for “Subtraction”

Oncologists began asking: Can we cut back on oxaliplatin without losing benefits? The answer, it turns out, depends on the patient and the regimen.

Shorter Durations for Selected Patients

The IDEA collaboration—a global analysis of 12,834 patients—tested 3 months vs. 6 months of oxaliplatin-based ACT. While 3 months was slightly less effective overall (74.6% vs. 75.5% 3-year DFS), subgroup analysis revealed key exceptions:

  • Patients with T3N1 tumors (low-risk stage III) had similar outcomes with 3 or 6 months of treatment.
  • Those on CAPOX (capecitabine + oxaliplatin) fared just as well with 3 months.

Shorter treatment also cut long-term side effects (like permanent nerve damage) and reduced healthcare costs—critical wins for patients and systems alike. A 2019 meta-analysis supported this: shorter ACT didn’t worsen survival for stage III CRC patients when tailored to their needs.

Neoadjuvant Therapy: Adding Oxaliplatin Doesn’t Help

Doctors also tried extending oxaliplatin to neoadjuvant therapy (before surgery) or chemoradiotherapy (chemo + radiation). But trials like FOWARC (2018) and PETACC-6 (2018) showed no survival benefit—only more toxicity. For example, the FOWARC trial found 3-year DFS was identical (around 75%) whether patients got 5-FU + radiation, 5-FU/oxaliplatin + radiation, or oxaliplatin alone. Adding oxaliplatin here was unnecessary.

Local Chemotherapy: Cutting Back on HIPEC

Even hyperthermic intraperitoneal chemotherapy (HIPEC)—a targeted treatment for CRC that has spread to the abdomen—wasn’t spared. The PRODIGE 7 trial (2018) found that adding oxaliplatin to HIPEC after surgery didn’t improve survival but increased complications. For some patients, skipping oxaliplatin in HIPEC might be safer.

The Future: Personalized Therapy Beyond “One-Size-Fits-All”

The biggest takeaway? Adjuvant therapy must be tailored to the patient. As Chen and colleagues note, future research should focus on:

  • Molecular profiling: Identifying genetic markers that predict who will benefit from oxaliplatin (or who won’t).
  • Subgroup selection: Using tumor characteristics (like location or peritoneal spread) to guide treatment.
  • Shared decision-making: Working with patients to weigh benefits (e.g., longer survival) against risks (e.g., nerve damage).

This aligns with recommendations from the American Society of Clinical Oncology (ASCO), which now advises a “shared decision-making” approach for oxaliplatin duration. The National Comprehensive Cancer Network (NCCN) also supports oxaliplatin-based ACT for stage II/III CRC—but only for patients who can tolerate it.

Conclusion: Balancing Benefit and Harm

For decades, the mantra in CRC therapy was “more is better.” But today, the focus is on balance. Adding oxaliplatin revolutionized adjuvant therapy—but only for those who truly need it. For others, shorter durations or fewer drugs can offer the same survival benefits with less suffering.

As Chen and colleagues write, the future of CRC treatment lies in “rational addition and subtraction”—using data to tailor care to each patient’s unique needs. By moving beyond “one-size-fits-all” regimens, we can save lives and preserve quality of life.

References (original study citations):
Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
Grothey A, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–1188.
Schmoll HJ, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 2015;33:3733–3740.
Taieb J, et al. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treat Rev 2019;75:1–11.

Original study DOI: doi.org/10.1097/CM9.0000000000000473

Was this helpful?

0 / 0